Sunday, January 6, 2013

The giant, gaping hole in Sandy Hook reporting

 

Some critics suggest these official omissions are motivated by a desire to protect the drug companies from ruinous product liability claims. Indeed, pharmaceutical manufacturers are nervous about lawsuits over the “rare adverse effects” of their mood-altering medications. To avoid costly settlements and public relations catastrophes – such as when GlaxoSmithKline was ordered to pay $6.4 million to the family of 60-year-old Donald Schnell who murdered his wife, daughter and granddaughter in a fit of rage shortly after starting on Paxil – drug companies’ legal teams have quietly and skillfully settled hundreds of cases out-of-court, shelling out hundreds of millions of dollars to plaintiffs. Pharmaceutical giant Eli Lilly fought scores of legal claims against Prozac in this way, settling for cash before the complaint could go to court while stipulating that the settlement remain secret – and then claiming it had never lost a Prozac lawsuit.

All of which is, once again, to respectfully but urgently ask the question: When on earth are we going to find out if the perpetrator of the Sandy Hook school massacre, like so many other mass shooters, had been taking psychiatric drugs?

The giant, gaping hole in Sandy Hook reporting

No comments: